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Sir,
Thyroxine is a hormone known to have unique pharma-
cokinetics and its intestinal absorption is affected by a
number of factors. Variation in the absorption of
thyroxine can occur due to its interaction with food (if not
taken on empty stomach), decreased intestinal transit
time in case of diarrhoea and different preparations and
brands of thyroxine used.1 Patients with markedly
reduced intestinal absorptive area, such as those with
intestinal failure or short gut syndrome, may not be able
to absorb even a small amount of thyroxine taken orally.
We recently encountered a patient who was started on
parenteral nutrition and required life-long thyroxine
replacement.
A 45 years woman was brought to our hospital with
complaints of severe abdominal pain for the past few
hours. She was a known case of hypothyroidism and
protein-C deficiency and was taking thyroxine and
warfarin for these conditions respectively. On initial
evaluation, the abdominal pain was out of proportion
to the findings noted on examination. Laboratory
investigations revealed a sub-therapeutic International
Normalized Ratio (INR). A computed tomography scan
of the abdomen was consistent with superior mesenteric
vein thrombosis. Anti-coagulation with heparin was
started and decision was made to proceed with
laparotomy. Intra-operatively, she was noted to have
ischemic small intestinal loops and extensive small
bowel resection was performed. After recovering from
surgery, she was started on parenteral nutrition. One
month after the surgical procedure, the patient
complained of fatigue and cold intolerance. A Thyroid
Stimulating Hormone (TSH) level was obtained, which
was markedly above the normal range (55 mIU/L).
Thyroxine replacement was thus deemed necessary for
this patient. However, the route and method of
administration of thyroxine posed a clinical conundrum.
The patient was initially administered intravenous
injections of thyroxine.2 However, no definitive approach
could be adopted for long-term thyroxine replacement in
her case. The commercially available preparations of
thyroxine are not suitable for subcutaneous injection.
While there are occasional reports of administration of
thyroxine rectally,3 there are no large scale studies
to establish their efficacy and reliability. Even for
intravenous injections, the frequency and dosage for
long-term replacement have not been standardized.4,5
Furthermore, the intravenous formulation of thyroxine is
not widely available in many countries of the world
including Pakistan. The cost involved in obtaining
and administering thyroxine intravenously for life in
such patients, especially in developing countries, is
prohibitive and further compounds this problem. There is
a dire need to conduct large scale clinical studies to
devise low cost, feasible and effective approaches for
the long-term, intravenous replacement of thyroxine in
patients on total parenteral nutrition. Furthermore, novel
inventions of subcutaneous or sublingual thyroxine
therapy are urgently needed for such clinical problems.
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